• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>AutoZone

AutoZone

AutoZone Inc AZO 3 Star

Last Price$696.96Day Change (%)-0.57%
Open Price$702.00Day Change ($)-3.98
Day Range693.59–702.0052-Week Range491.93–705.00

As of Mon 8/3/2015 5:15:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Gabelli & Company’s 39th Annual Automotive Aftermarket Symposium

    Gabelli & Company’s 39th Annual Automotive Aftermarket Symposium

  2. Plenty of Roadway for Auto-Parts Retailers

    Despite a recent sales-growth slowdown, we remain positive on narrow-moat AutoZone , Genuine Parts, Advance, and O'Reilly over the longer run.

  3. Seeking Small-Cap Moats: Monro Muffler Brake

    Monro's acquisition strategy is creating a virtuous cost-advantage cycle, but shares don’t come cheap at the moment, writes Morningstar’s Todd Wenning.

  4. Two Auto-Parts Retailers Gain Moats From Growing Cost Advantages, Industry Consolidation

    O'Reilly and Advance have expanded their store bases through acquisitions and organic growth, enhancing their cost advantages.

  5. Our Outlook for the Credit Markets

    The corporate bond market will probably struggle to return much above break-even in 2014.

  6. Should Investors Continue to Buy Fixed Income Given the Potential “Bond Bubble”?

    AutoZone's AZO third-quarter results came in about as we expected. Our fair value estimate remains $103 per share. Revenue increased by 5.9% to $1.417 billion, led by expansion and a 2.1% rise in same-store sales (up from 0.4% in the second quarter). While its comparable revenue growth still ...

  7. Specialty Retail: Ad Hoc Opportunity

    Each specialty retail segment is not like the others; our analysts have scoured the industry’s credit offerings to find the best deals.

  8. Hunting for Good Buys in the Retail Sector

    Top managers are divided over what looks like a bargain and what doesn't.

  9. Tracking Funds as They Migrate Across the Style Box

    There are big shifts from Fidelity Dividend Growth and Fairholme.

  10. HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind

    HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.